Photo of Yakup Ergün from batmanpetrol.com
Jul 8, 2024, 19:24
Yakup Ergün: PRODIGE 23: Long-term results
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared insight about a study by Thierry Conroy et al. on X:
“PRODIGE 23: Long-term results
Neoadj FOLFIRINOX vs SoC (CRT)
- 7y-DFS: 67.6 vs 62.5%
- 7y-MFS:79.2 vs 72.3%
- 7y-OS:81.9 vs76.1%
Induction chemotherapy with mFOLFIRINOX improves OS in LARC patients.”
Read the article.
Source: Yakup Ergün/X
7-year disease-free survival
7-year metastasis-free survival
7-year overall survival
Antalya City Hospital
cancer
Cancer research
CRT
induction chemotherapy
LARC
locally advanced rectal cancer
long-term results
medical oncology
mFOLFIRINOX
neoadjuvant FOLFIRINOX
OncoDaily
Oncology
PRODIGE 23
Standard of Care
Thierry Conroy
Yakup Ergün
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 23, 2024, 10:05
Oct 23, 2024, 10:00
Oct 23, 2024, 09:57
Oct 23, 2024, 07:06
Oct 23, 2024, 06:59
Oct 23, 2024, 05:24
Oct 23, 2024, 05:17